Achieve Life Sciences, Inc. (ACHV) News
Filter ACHV News Items
ACHV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACHV News Highlights
- ACHV's 30 day story count now stands at 4.
- Over the past 23 days, the trend for ACHV's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest ACHV News From Around the Web
Below are the latest news stories about ACHIEVE LIFE SCIENCES INC that investors may wish to consider to help them evaluate ACHV as an investment opportunity.
Achieve Life Sciences Announces Participation at Upcoming Investor ConferencesSEATTLE and VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will be participating at three upcoming conferences. H.C. Wainwright 25th Annual Global Investment ConferenceDate: Monday, September 11, 2023Event: On-demand PresentationT |
ACHV: 2Q:23 ResultsBy John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Second Quarter 2023 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported second quarter 2023 results in a press release on August 14th and held a conference call the following morning. The company concurrently filed its Form 10-Q with the SEC. 2023 highlights to date include impressive topline results from the |
Q2 2023 Achieve Life Sciences Inc Earnings CallQ2 2023 Achieve Life Sciences Inc Earnings Call |
Individual investors account for 59% of Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) ownership, while institutions account for 40%Key Insights Significant control over Achieve Life Sciences by individual investors implies that the general public has... |
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate UpdateCompany to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Highlights Pub |
Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and WebcastSEATTLE and VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2023 financial results on Monday, August 14, 2023, and host a conference call and webcast on Tuesday, August 15, 2023, at 8:30 AM EDT. To access the webcast, please |
Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual MeetingSEATTLE and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced participation on a panel during the 2023 American Society of Pharmacognosy (ASP) Annual Meeting, being held at the Bethesda North Marriott Hotel Conference Center in Rockville, MD from July 22-26, 2023. Achi |
Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)Cytisinicline 6- and 12-week dosing schedules, with behavioral support, demonstrated “smoking cessation efficacy and excellent tolerability” Supports potential for cytisinicline to be the first pharmacotherapy approved for smoking cessation in nearly two decades SEATTLE and VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced the publication in JAMA of the results from the Phase 3 ORCA-2 randomized placebo-controlled clinical |
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct OfferingSEATTLE and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registe |
ACHV: ORCA-3 ToplineBy John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT ORCA-3 Topline Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported topline results from the second Phase III pivotal trial of cytisinicline on May 23, 2023. Results were discussed with analysts and investors in a conference call held that morning. On average, odds ratios were lower than that achieved in ORCA-2, but |